Detalhe da pesquisa
1.
Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Am J Hematol
; 94(10): 1113-1122, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31321805
2.
Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.
Leukemia
; 38(1): 149-159, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37848634
3.
Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.
Cancer Commun (Lond)
; 44(3): 408-432, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38407943
4.
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.
J Hematol Oncol
; 16(1): 5, 2023 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36681817
5.
Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies.
Leuk Lymphoma
; 61(14): 3440-3450, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32840399
6.
Improved in vivo detection of atherosclerotic plaques with a tissue factor-targeting magnetic nanoprobe.
Acta Biomater
; 90: 324-336, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30954623